Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thiostrepton - RS Oncology

Drug Profile

Thiostrepton - RS Oncology

Alternative Names: RSO-021

Latest Information Update: 12 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RS Oncology
  • Developer RS Oncology; University of Leicester
  • Class Antineoplastics; Cyclic peptides; Oligopeptides; Peptides; Peroxidases; Small molecules
  • Mechanism of Action Peroxiredoxin III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Malignant pleural effusion; Malignant-mesothelioma; Solid tumours
  • Preclinical Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 11 Oct 2023 Pharmacodynamics data from preclinical studies in Malignant mesothelioma presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
  • 12 Sep 2023 RS Oncology completes the dose-escalation part of a phase I trial in malignant pleural mesothelioma in the UK (NCT05278975)
  • 06 Sep 2023 Preclinical trials in Malignant mesothelioma in USA (Intraperitoneal) (RS Oncology pipeline, September 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top